[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-dysregulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-dysregulation":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,80,133,168,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641447","phase-2-naive-t-cell-deplete-grafts-for-gvhd-prevention-in-non-malignant-diseases-100641447",false,"NCT07660783","Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases","A Phase II Prospective Study Evaluating Selective Depletion of CD45RA+ (Naïve) T Cells (TND) From Peripheral Blood Stem Cell (PBSC) Grafts for Prevention of Graft Versus Host Disease (GVHD) in Non-Malignant Diseases (NMDs)","Inclusion Criteria:\n\n* Considered appropriate candidate for allogeneic HCT following low dose (4Gy) TBI containing-conditioning and have one of the following diagnoses: A) BMF B)Hemoglobinopathies C)PID D) Autoimmune cytopenias E) Immune dysregulation F) HLH G) Other NMD treatable by HCT and NMD that is not clearly defined (a patient with a NMD for whom genetic testing has been done and a genetic mutation responsible for their NMD phenotype has not been identified) are eligible for the study following discussion with and approval by the protocol PI\n* Patients aged 6 months- 5 years old (inclusive) at the time of informed consent\n* Patient with suitable HCT donor (see inclusion criteria below)\n* Recipient informed consent\u002Fassent (13 years and older), and\u002For legal guardian permission must be obtained\n\nExclusion Criteria:\n\n* Patient with aplastic anemia\n* Patients with severe combined immunodeficiency (SCID)\n* Fanconi anemia\n* Dyskeratosis congenita\n* Patient weight \\> 100 kg\n* Patients who are positive for HIV-1, HIV-2\n* Patients with current neoplastic disorders\n* Patients with uncontrolled infections for whom HCT is considered contraindicated by the consulting infectious disease physician.\n* Patients with organ dysfunction including A) Renal insufficiency B) Impaired cardiac function C)Impaired pulmonary function D) Liver dysfunction\n* Patients who are pregnant or breast-feeding\n* Patients on other experimental protocols for prevention of GVHD\n* Patients of childbearing age who are presumed to be fertile and are unwilling to use an effective birth control method or refrain from sexual intercourse during and for 12 months post-HCT\n* Patients with any other significant medical conditions that would make them unsuitable for transplantation, as determined by the PI\n* Patients with a known hypersensitivity to tacrolimus or MMF","ALL","6 Months","50 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant diseases requiring hematopoietic cell transplantation. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.",[27,28,29,30,31,32,33],"Bone Marrow Failure","Hemoglobinopathies","Primary Immune Deficiency (PID)","Autoimmune Cytopenia","Immune Dysregulation","Hemophagocytic Lymphohistiocytosis (HLH)","Non Malignant Disorders","NOT_YET_RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2035-09",{"name":44,"class":45},"Fred Hutchinson Cancer Center","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100642002","toxin-exposure-and-immune-dysregulation-in-non-hodgkin-lymphoma-100642002","NCT07652580","Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma","Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Across the Military Healthcare System","TOXNHL","Inclusion Criteria:\n\n* Age 4 years old and older with a clinical diagnosis of B-cell NHL.\n* Must be willing to undergo phlebotomy and\u002For skin punch biopsy.\n* Must be willing to undergo whole genome sequencing, which includes return of primary and secondary findings.\n\nExclusion Criteria:\n\n* Has any condition that, in the opinion of the Principal Investigator, contraindicates participation in this study. Examples of situation that may contraindicate participation include but are not limited to a) some cases of cerebral vascular accidents where an individual no longer has the capacity to make their own medical decisions and a conservator or responsible family member is not available and b) an individual has active suicidal ideation and is a danger to themselves at the time of enrollment.\n* Does not have access to health care and primary care clinician.\n* Actively undergoing induction treatment for NHL.","4 Years",{"count":57,"type":21},300,"OBSERVATIONAL","The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether specific exposures and germline variants are associated with B-cell NHL subtype, immune dysfunction, and clinical outcomes. Participants will complete exposure and medical-history surveys, provide biospecimens for immune and genomic testing, and may be followed annually for up to 3 years.",[61,62,63,31],"Non-Hodgkin Lymphoma","Lymphoma Non-Hodgkin","B-cell Lymphoma",[65,66,67,68],"Immunodeficiency","Lymphoma","Exposure","Genetics","RECRUITING","2026-06-11",{"date":72,"type":38},"2026-06-17",{"date":74,"type":38},"2025-05-01",{"date":76,"type":21},"2028-05-01",{"name":78,"class":45},"Henry M. Jackson Foundation for the Advancement of Military Medicine",3,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":108,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100614826","phase-2-hematopoietic-stem-cell-transplantation-hsct-for-common-variable-immunodeficiency-cvid-and-other-autoimmune-manifestations-of-primary-immune-regulatory-disorders-pird-100614826","NCT07284641","Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)","CVID\u002FPIRD","Inclusion Criteria:\n\n1. Patient, parent, or legal guardian must have given written informed consent. For pediatric subjects who are developmentally able, assent or affirmation will be obtained.\n2. Male or female, 5 through 40 years old, inclusive, at the time of informed consent.\n3. Patients must have evidence of common variable immunodeficiency (CVID) or other autoimmune manifestation of a primary immune regulatory disorder (PIRD). Genetic screening is required by a targeting gene panel to determine presence of genetic variations that may lead to inborn errors of immunity.\n\n   Examples of such diseases include, but are not limited to:\n   * Common variable immunodeficiency (CVID)\n   * Combined Immunodeficiency (CID)\n   * Immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX syndrome), IPEX like syndromes\n   * Combined immunodeficiency with defects in T-cell-mediated immunity, including Omenn syndrome and DiGeorge Syndrome\n   * Chronic Granulomatous Disease (CGD)\n   * Signal Transducer and Activator of Transcription (STAT 1) Gain of Function (STAT1 GOF)\n   * Signal Transducer and Activator of Transcription (STAT 3) Gain of Function (STAT3 GOF)\n   * Hypomorphic Recombination-Activating Genes (RAG) 1 and RAG 2\n   * CD40 or CD40L deficiency\n   * Mendelian Susceptibility to Mycobacterial Disease\n   * GATA-binding factor 2 (GATA2) Associated Immunodeficiency\n   * Mouth and Genital Ulcers with Inflamed Cartilage Syndrome (MAGIC)\n4. Must have previously failed, due to lack of response or intolerance, mycophenolate mofetil and a B cell-depleting antibody, such as Rituximab\n5. Glomerular Filtration Rate (GFR) ≥50 mL\u002Fmin\u002F1.73 m2\n6. Aspartate Aminotransferase (AST) ≤4x upper limit of normal\n7. Alanine Aminotransferase (ALT) ≤4x upper limit of normal\n8. Direct bilirubin ≤ 2.5 mg\u002FdL\n9. Human Immunodeficiency Virus (HIV) negative by serology and PCR\n10. Human T-cell Lymphotropic Virus (HTLV) negative by serology\n11. Cardiac ejection fraction ≥ 40% or shortening fraction ≥26%\n12. Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) ≥40% predicted for age\n13. Peripheral Capillary Oxygen Saturation (SpO2) of \\>92% at rest on room air\n14. Subjects must be a minimum of 8 weeks post-solid organ transplant prior to start of conditioning, if applicable\n15. Negative pregnancy test for females \\>10 years old or who have reached menarche, unless surgically sterilized.\n16. All females of childbearing potential and sexually active males must agree to use a FDA approved method of birth control for up to 12 months after stem cell transplant or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause birth defects.\n17. Subject and\u002For parent guardian informed of the potential risks of infertility following stem cell transplant and advised to discuss sperm banking or oocyte harvesting.\n18. Transplant endorsement from clinical immunologist\n\nExclusion Criteria:\n\n1. Allergy to Dimethylsulfoxide (DMSO) or any other ingredient used in the manufacturing of the stem cell product\n2. Uncontrolled systemic infection, as determined by the appropriate confirmatory testing e.g. blood cultures, Polymerase chain reaction (PCR) testing, etc.\n3. Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of stem cell transplant\n4. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.","5 Years","40 Years",{"count":90,"type":21},25,[24],"This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD).",[94,95,31,96,97,98,99,100,101,102,103,104,105,106,107],"Common Variable Immunodeficiency (CVID)","Primary Immune Regulatory Disorder","DiGeorge Syndrome","STAT 1 Gain of Function","STAT 3 Gain of Function","Hypomorphic RAG1 Deficiency","CD40 Ligand Deficiency","Mendelian Susceptibility to Mycobacterial Disease","GATA2 Associated Immunodeficiency","CD40 Deficiency","Hypomorphic RAG2 Deficiency","Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome","Omenn Syndrome","Chronic Granulomatous Disease",[109,110,111,112,113,114,115,116,117,118,96,119,107,97,98,120,121,101,102,122],"HSCT","CVID","PIRD","primary immune regulatory disorder","common variable immunodeficiency","IPEX like syndromes","Immune dysregulation","polyendocrinopathy","enteropathy","X-linked (IPEX syndrome)","Combined Immunodeficiency","Hypomorphic RAG 1 and RAG 2","CD40 or CD40L deficiency","Inflamed Cartilage Syndrome (MAGIC)","2026-05-13",{"date":125,"type":38},"2026-05-15",{"date":127,"type":38},"2026-05-04",{"date":129,"type":21},"2031-02-01",{"name":131,"class":45},"Paul Szabolcs",1,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100428681","phase-2-treatment-for-immune-mediated-pathophysiology-100428681","NCT04862221","TReatment for ImmUne Mediated PathopHysiology","A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatric Patients","TRIUMPH","Inclusion Criteria:\n\n1. Patient with liver injury of ≤ 6 weeks duration resulting in an international normalization ratio (INR) of ≥ 1.5 or \\\u003C 2.0 (not corrected by vitamin K) with evidence of hepatic encephalopathy (HE), INR of ≥ 1.5 or \\\u003C 2.0 for at least 7 days duration without evidence of HE or INR ≥ 2.0 without evidence of HE.\n2. Age is greater than or equal to 1 year and less than 18 years of age.\n3. Patient or their legally authorized representative(s) (LAR) must consent (and assent, if applicable) to be in the study and must have signed and dated an approved informed consent form which conforms to federal and institutional guidelines.\n4. Females of reproductive potential should not plan on conceiving children during the study and must agree to use a medically accepted form of contraception.\n\nExclusion Criteria:\n\n1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes simplex virus (HSV) or adenovirus infection\n2. Travel within the past 3 months to an area highly endemic for Hepatitis E\n3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of consanguinity and\u002For central nervous system (CNS) dysfunction that is exaggerated compared to the degree of liver dysfunction (as judged by the site investigator) will not be enrolled until results of rapid genetic testing are available. Turn-around time for genetic testing results is estimated to be 72-96 hours.\n4. Aplastic anemia as defined by standardized criteria \\[1\\] diagnosed prior to enrollment\n5. Diagnosis of autoimmune Hepatitis (AIH)\n6. Diagnosis of acute Wilson disease\n7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an exclusion for entry into the Trial.\n8. Diagnosis of acute drug or toxin-induced liver injury\n9. History of recreational drug use within the past 4 weeks\n10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies or an experimental drug or device within the past 6 weeks\n11. Liver injury due to ischemia\n12. Liver dysfunction diagnosed more than 6 weeks prior to screening\n13. History of allergy to horse dander\n14. Sepsis\n15. Imminent risk of death as judged by the clinical site investigator, including but not limited to; signs of cerebral herniation at the time of enrollment and presence of intractable arterial hypotension\n16. Solid organ or stem cell transplant recipient\n17. Pregnant or breast-feeding at the time of proposed study entry\n18. Clinical AIDS or HIV positive\n19. History of any form of malignant neoplasm and\u002For tumors treated within five years prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer) or where there is current evidence of recurrent or metastatic disease\n20. Received a live-virus vaccine within 4 weeks of study entry\n21. Patients with positive respiratory secretion testing for respiratory viral infection including SARS-CoV-2, influenza and respiratory syncytial virus only if they also have declining respiratory function\n22. Psychiatric or addictive disorders that would preclude obtaining informed consent\u002Fassent\n23. Patient is unwilling or unable to adhere with study requirements and procedures\n24. Currently receiving other experimental therapies","1 Year","18 Years",{"count":144,"type":21},163,[24],"TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.",[148,149,150,151,31],"Acute Liver Failure","Fulminant Hepatic Failure","Hepatic Encephalopathy","Acute Liver Injury",[153,154,155,156],"hepatic insufficiency","liver diseases","liver failure","anti-thymocyte agents","2026-05-11",{"date":159,"type":38},"2026-05-14",{"date":161,"type":38},"2022-02-09",{"date":163,"type":21},"2027-02",{"name":165,"class":166},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",24,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":132},"100579818","phase-4-assessment-of-metformin-for-restoration-of-immune-homeostasis-in-hiv-and-hiv--individuals-with-a-history-of-injection-drug-use-100579818","NCT06829238","Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use","Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use (MET-IH)","(MET-IH)","Inclusion Criteria:\n\n* Provision of signed and dated informed consent.\n* Stated willingness to comply with all study procedures and availability for the study duration.\n* Aged 18 to 64 years old.\n* Weight of at least 110 lbs.\n* Body Mass Index (BMI) of 18.5-40. Enrollment of individuals with BMI \\>40, deemed in good health, may be considered with approval.\n* Willingness to receive Jynneos (MPOX) and Capvaxvie vaccines.\n* Ability to take oral medication and willingness to adhere to the metformin treatment regimen.\n* History of injection opioid, amphetamine, and\u002For cocaine use within the past 10 years (self-report).\n* Use of non-prescription opioid, amphetamine, and\u002For cocaine within the past 30 days (self-report).\n* Clinically confirmed urine drug screen for opioid, amphetamine, and\u002For cocaine within the past 30 days.\n* Serum CRP \\> 3 mg\u002FdL.\n* Glucose level between 70-180 mg\u002FdL (non-fasting).\n* Hemoglobin A1c (HbA1c) of 5.0-6.4%.\n* CD4 count \\> 200 cells\u002Fml.\n* If HIV-positive, HIV viral load \\\u003C 200 copies\u002Fml.\n* If HIV-positive, on anti-retroviral therapy (ART) for \\>12 months.\n\nExclusion Criteria:\n\n* Inability to give informed consent.\n* Refusal or inability to have blood drawn.\n* Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, platelet disorder requiring precautions).\n* Pregnant or nursing individuals.\n* Diabetes mellitus.\n* History of severe renal impairment or eGFR \\\u003C60 mL\u002Fmin\u002F1.73m².\n* Creatinine clearance \\\u003C60 mL\u002Fmin.\n* History of liver disease.\n* ALT\u002FAST \\> 3× the upper limit of normal.\n* Total bilirubin \\>1.4 mg\u002FdL.\n* Albumin \\\u003C3.5 g\u002FdL.\n* Prothrombin \\>1.5× the upper limit of normal.\n* AUDIT-C score ≥8.\n* Hemoglobin \\\u003C9.0 g\u002FL.\n* Absolute neutrophil count \\\u003C1,000\u002FmL.\n* Platelet count \\\u003C100,000\u002FmL.\n* History of acute or chronic metabolic acidosis.\n* Serum bicarbonate \\\u003C22 mEq\u002FL.\n* Anion gap \\>10 mEq\u002FL.\n* Serum lactate \\>2.2 mmol\u002FL.\n* Serum vitamin B12 \\\u003C250 pg\u002FmL.\n* History of chronic diarrhea.\n* Current use of metformin or other diabetes medications.\n* History of myocardial infarction, endocarditis, stroke, heart failure, chronic obstructive pulmonary disease, or sepsis.\n* Use of medications such as furosemide, nifedipine, ranolazine, vandetanib, or cimetidine (current or within the past 30 days).\n* Active hepatitis B infection.\n* Hepatitis C infection within 6 months of study entry; individuals with prior hepatitis C must be at least 6 months post-treatment with direct-acting antivirals.\n* Previous receipt of Jynneos or pneumococcal vaccine within the past two years (self-report).\n* Severe allergic reaction to metformin, Jynneos, or Capvaxvie (self-report). Blood donations exceeding 450 mL in the 8 weeks prior to enrollment, accounting for study-related blood draws.\n* Any medical, psychiatric, social condition, or responsibility that, in the investigator's judgment, could interfere with study procedures.","64 Years",{"count":178,"type":21},100,[180],"PHASE4","This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.",[183,31,184,185],"Systemic Inflammation","Injection Drug Use","HIV",[187,188,189,190],"Metformin","Immune restoration","Vaccine response","People who inject drugs (PWID)","2026-04-17",{"date":193,"type":38},"2026-04-22",{"date":195,"type":38},"2025-04-07",{"date":197,"type":21},"2029-11-30",{"name":199,"class":45},"University of Alabama at Birmingham",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":207,"sex":16,"minAge":4,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":213,"conditions":214,"keywords":219,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":132},"100622536","immune-cells-role-in-lung-cancer-and-their-use-in-anticancer-immunotherapies-and-inflammatory-lung-disease-100622536","NCT07384897","Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease","IMMUNOPUMON2","Inclusion Criteria:\n\n* Diagnosis of lung cancer\n* Presence of precancerous lung lesions\n* Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \\[COPD\\]) prior to any treatment\n* Control group: individuals without known lung disease\n* Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)\n* Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected\n\nExclusion Criteria:\n\n* Systemic corticosteroid therapy \\> 10 mg\u002Fday prednisone (or equivalent)\n* Acute infection at the time of inclusion\n* Refusal or inability to provide informed consent (or assent, when applicable)\n* Chronic inflammatory lung disease currently treated with immunosuppressive therapy",true,"80 Years",{"count":210,"type":21},425,[212],"NA","This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).\n\nThe investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.\n\nAlthough recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.\n\nThe knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.",[215,216,217,218,31],"Lung Cancer (Diagnosis)","Sarcoidosis","Chronic Obstructive Pulmonary Disease","Immunotherapy Resistance",[220,221,216,217,222,223,224,31,225,218,226,227,228,229,230,231,232,233],"lung cancer","Non-Small Cell Lung Cancer","COPD","Immune Cells","Tumor Microenvironment","Immunotherapy","Immune Profiling","Myeloid Cells","Neutrophils","Dendritic Cells","Inflammation","Chronic Inflammation","Immune suppression","Emergency myelopoiesis","2026-01-26",{"date":236,"type":38},"2026-02-03",{"date":238,"type":38},"2025-02-17",{"date":240,"type":21},"2032-02-17",{"name":242,"class":45},"Université Catholique de Louvain"]